She was a lyric soprano soloist in various Oratorio works and in the Opera Stage. She was also a very accomplished pianist and accompanist and was the accompanist of National Artist for Music, Jovita Fuentes for a number of years. Apart from being an extraordinary musician, she was also an exceptional athlete as a competitive swimmer. She was part of the Philippine swimming team who first competed internationally in Hong Kong. Upon her return to the Philippines in , she established a singing group with the same idea.
|Published (Last):||1 September 2011|
|PDF File Size:||1.17 Mb|
|ePub File Size:||15.42 Mb|
|Price:||Free* [*Free Regsitration Required]|
Select Page Leadership Team At Silicon Therapeutics we have assembled a diverse leadership team with deep experience across disciplines ranging from physics and computer aided drug design, to chemistry and structural biology. He has spent his entire career in the healthcare sector working across a number of industries including drug discovery, CRO, investment banking, consulting, venture capital, private equity and non-profits. He joined Silicon from Evelo Biosciences, where he served as Chief of Medical Oncology and led oncology discovery as well as the IND and clinical development of their first microbial cancer immune therapy.
Prior to these appointments, he led the Oncology Translational Laboratories at Novartis, and various discovery and translational programs at Biogen.
He completed his postdoctoral fellowship at the Whitehead Institute in the laboratory of Professor Rudolf Jaenisch. Humphrey has over publications and patents in fields including oncology, neuroscience, rheumatology, and diagnostics, and additionally holds an MS in Bioinformatics from Brandeis University.
Winter has held research leadership positions in pharmaceutical companies and emerging biotechnology firms over the past 15 years. During that time, he has delivered ten targeted cancer therapies into clinical development. The first biologist recruited to Blueprint, Dr.
Prior to Blueprint, Dr. Winter held senior research positions at Merck Research Laboratories and Exelixis. He was also part of the senior management team and was involved in modeling services, methods development, and product management. Sherman is a leader in molecular simulations and computer-aided drug design, with over 80 publications covering novel methods and applications. He completed his Ph.
Sherman has published on a broad range of topics, including free energy simulations, molecular dynamics, induced-fit docking, virtual screening, lead optimization, selectivity design, cheminformatics, and protein design. He is also leading the Silicon Therapeutics office in China.
Before joining Silicon Therapeutics, he had spent 12 years in D. Shaw Research, where he played an early role in the design of the specialized Anton chip for molecular dynamics simulations, and he led the development of the methods and software for free energy calculations that are now widely used in the pharmaceutical industry.
His research interests include development of simulation methods, free energy calculations, structural immunology, protein folding and misfolding, and molecular design. Prior to Agios Therapeutics, Dr. Borella held project leadership positions at both Proteostasis and Synta Pharmaceuticals.
Vipin was most recently with IBM in their T. Vipin has over 10 years of experience of parallel programming and optimizing applications for CPUs, GPUs and other specialized hardware. Vipin is main author of a book chapter on multicore programming, over 30 refereed publications and has given multiple invited talks and has reviewed for multiple conferences and journals. She has worked with small to large size companies, partnering at all levels of the organization to drive proactive organizational change and strategic initiatives.
She also served as Head of Human Resources at Tokai Pharmaceuticals, where she established processes and analyzed company needs in the areas of compensation, benefits, safety, HR reporting training, organizational development and talent management. Throughout his career Steve has become an industry recognized expert in SBDD with extensive experience in applying computational tools to supporting new compound design and project decision making.
Steve joined Silicon Therapeutics from Takeda Pharmaceuticals San Diego, CA , where he was Associate Director of Chemistry and lead a team of 8 chemists and 2 computational scientists who supported projects across the portfolio.
Prior to Takeda, he spent 6 years in the medicinal chemistry groups at Eli Lilly and Abbvie where he gained unique experience in the early stages of drug discovery including: FBDD, novel approaches to hit ID and lead optimization, efficiency metrics, as well computational modeling and SBDD across different target classes. His research experience covers gastroenterology, immuno-oncology, inflammation, and autoimmune diseases.
Steve obtained and dual B. Holly Soutter is Director of Biophysics and Biochemistry at Silicon Therapeutics bringing more than a decade of experience in the pharmaceutical and biotech sectors. She joins us from X-Chem Pharmaceuticals where she led a group responsible for assay development and validation, protein expression and purification, protein characterization, structural biology, and biophysics. In her previous role at Pfizer, she provided structure-based drug design support for projects in multiple therapeutic areas including in oncology, anti-infectives, immunology, cardiovascular and inflammation.
She is co-inventor of multiple clinical candidates, co-author of 22 peer-reviewed manuscripts and two patents. Cecilia Bastos is the Director of Chemistry at Silicon Therapeutics, and brings more than 20 years of experience in medicinal chemistry, process development and cGMP manufacturing. She joins us from Aveo Pharmaceutical where she optimized and validated the manufacturing processes.
Prior to Aveo Pharmaceutical, she led the medicinal chemistry efforts at Proteostasis that resulted in the nomination of three clinical candidates. She was also responsible for the process development, optimization and cGMP manufacturing of these candidates. Before joining Proteostasis, she worked at Genzyme where she led multiple teams resulting in pre-clinical candidates for multiple projects including rare genetic diseases, cardiovascular disease, endocrinology, and malaria.
She is a co-inventor in more than 10 patents covering pre-clinical and clinical candidates, and has co-authored more than 15 peer-reviewed papers. She holds a Ph. He led several successful drug development programs in multiple therapeutic areas including oncology, ophthalmic, otic, immunology, dermatology and inflammation.
Taimi obtained his B. She joins us from AstraZeneca where she was the Biology lead on multiple Oncology programs responsible for developing and executing pre-clinical studies from target validation, lead generation and optimization to biomarker development. In his two years there he played an important role in developing laboratory and administrative operations while receiving training certifications in life sciences.
During his five years there, he became proficient in all aspects of laboratory logistics including metrology, hazardous waste management, hazardous shipping and receiving, compound management, sample quality control, project coordination, purchasing and inventory management.
Gino provides operational excellence to the Silicon laboratory operations and played a key role in the laboratory build-out supporting biology, chemistry and biophysics. He is a highly motivated team player who seeks solutions to all problems and believes there is no task too big or small.
PHSA, National Arts Center, Mt. Makiling, Los Banos, Laguna
23rd Awit Awards